StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Fair value share price - $9.64

<< Previous

Bullboard Posts

Next >>

Comment by Teddy3on Aug 31, 2021 2:07pm

153 Views

Post# 33788725

RE:RE:RE:RE:RE:RE:RE:RE:Fair value share price - $9.64

It's really incredible the SP drops 75% and SZLS revenue Q over Q drops 80% from over 2 million to just 400K and the employee's seem to pretend this is nothing. 80%!!! But Tripp said it will return nest Q so everyone should take his word. His word is solid and he is very good at projections. Remember when he projected 30 million in revenue in 2019 and finished with 140K?

I would not for any reason hold this on the fact you think covid revenue will return because Tripp said so. It's ludacriss. 400K don't even pay Tripp his salary.

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading